Patents by Inventor Daniel E. Petrillo

Daniel E. Petrillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
    Patent number: 10259794
    Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 16, 2019
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Roger P. Bakale, Dale R. Mowrey, Daniel E. Petrillo, Sander Kluwer
  • METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES
    Publication number: 20170369451
    Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
    Type: Application
    Filed: December 23, 2015
    Publication date: December 28, 2017
    Inventors: Shawn P. ALLWEIN, Roger P. BAKALE, Dale R. MOWREY, Daniel E. PETRILLO, Sander KLUWER
  • Phase transfer catalyzed glycosidation of an indolocarbazole
    Publication number: 20040024196
    Abstract: The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Application
    Filed: July 31, 2003
    Publication date: February 5, 2004
    Inventors: Daniel E Petrillo, Steven A. Weissman, Shouichi Hiraga, Nobuya Satake, Kai Rossen
  • Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
    Patent number: 6642237
    Abstract: &ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: November 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James R. Tata, Kevin T. Chapman, Joseph Leslie Duffy, Nancy J. Kevin, Yuan Cheng, Thomas A. Rano, Fengqi Zhang, Tracy Huening, Brian Anthony Kirk, Zhijian Lu, Subharekha Raghavan, Fred J. Fleitz, Daniel E. Petrillo, Joseph D. Armstrong, III, Richard J. Varsolona, David Askin, R. Scott Hoerrner, Robert Purick
  • Hydrohalide salts of an HIV protease inhibitor
    Publication number: 20030125336
    Abstract: Pharmaceutically acceptable hydrochloride and hydrobromide salts of Compound A are disclosed, wherein Compound A is of formula: 1
    Type: Application
    Filed: May 30, 2002
    Publication date: July 3, 2003
    Inventors: Fred J. Fleitz, Daniel E. Petrillo, Yaling Wang, Russell R. Ferlita, David C. Dubost, Joseph D. Armstrong
  • Phase transfer catalyzed glycosidation of an indolocarbazole
    Patent number: 6555677
    Abstract: The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: April 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Daniel E. Petrillo, Steven A. Weissman, Shouichi Hiraga, Nobuya Satake, Kai Rossen
  • Phase transfer catalyzed glycosidation of an indolocarbazole
    Publication number: 20020058803
    Abstract: The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Application
    Filed: October 22, 2001
    Publication date: May 16, 2002
    Inventors: Daniel E. Petrillo, Steven A. Weissman, Shouichi Hiraga, Nobuya Satake, Kai Rossen